Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29113195
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Advances in targeting the transforming growth factor ?1 signaling pathway in lung
cancer radiotherapy
#MMPMID29113195
Lu Z
; Tang Y
; Luo J
; Zhang S
; Zhou X
; Fu L
Oncol Lett
2017[Nov]; 14
(5
): 5681-5687
PMID29113195
show ga
Lung cancer was demonstrated to be the most lethal type of malignant tumor
amongst humans in the global cancer statistics of 2012. As one of the primary
treatments, radiotherapy has been reported to induce remission in, and even cure,
patients with lung cancer. However, the side effects of radiotherapy may prove
lethal in certain patients. In past decades, the transforming growth factor ?1
(TGFB1) signaling pathway has been revealed to serve multiple functions in the
control of lung cancer progression and the radiotherapy response. In mammals,
this signaling pathway is initiated through activation of the TGFB1 receptor
complex, which signals via cytoplasmic SMAD proteins or other downstream
signaling pathways. Multiple studies have demonstrated that TGFB1 serves
important functions in lung cancer radiotherapy. The present study summarized and
reviewed recent progress in elucidating the function of the TGFB1 signaling
pathway in predicting radiation pneumonitis, as well as current strategies for
targeting the TGFB1 signaling pathway in lung cancer radiotherapy, which may
provide potential targets for lung cancer therapy.
free
free
free
